# Bahamas Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Bahamas HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Bahamas (BHS)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.7M
- Products: 38
- Buyer markets: 14
- Average CAGR: +25.9%
- Global sector size: $430.5B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $186.3B | $342.7K | $70.5B | +3.5% | 10 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $82.5B | $6.2 | $30.7B | -22.2% | 2 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $16.4B | $199.9 | $29.5B | +98.9% | 1 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.4B | $6.3 | $25.9B | -22.1% | 2 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $891.2K | $11.7B | -21.1% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $11.3B | $5.4K | $6.1B | +2.2% | 6 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $4.4B | $38.1K | $6.0B | +19.3% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $13.1B | $7.2K | $5.2B | -3.2% | 4 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $7.9B | $3.5K | $4.7B | +10.9% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $10.9B | $960.5 | $4.6B | -8.1% | 4 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $8.5B | $990.0 | $4.3B | +74.2% | 1 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $9.3B | $7.1K | $3.6B | +5.0% | 1 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.2B | $100.0 | $2.8B | -17.6% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $8.5K | $2.2B | +716.4% | 2 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $6.7K | $2.0B | +17.9% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.7B | $16.8K | $1.7B | +34.6% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.9B | $7.2K | $1.7B | +7.0% | 2 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $12.9K | $1.4B | +28.1% | 1 | +0.0% |
| HS 300432 - Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | $2.8B | $30.3K | $1.3B | -50.5% | 2 | +0.0% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $2.5K | $1.3B | -55.0% | 1 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $0.7 | $1.3B | -41.8% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $3.1B | $128.0K | $1.2B | +43.0% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $1.9B | $14.1 | $1.1B | +19.0% | 1 | +0.0% |
| HS 293134 - Organo-inorganic compounds: organo-phosphorus derivatives, sodium-3-(hydroxysilyl)propyl methylphosphonate | $590.5M | $15.3 | $958.1M | -64.4% | 1 | +0.1% |
| HS 290220 - Cyclic hydrocarbons: benzene | $1.4B | $35.1K | $895.3M | -1.2% | 1 | +0.0% |
| HS 300449 - Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $67.1 | $841.5M | -15.5% | 1 | +0.0% |
| HS 330290 - Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $208.0 | $803.3M | +127.1% | 1 | +0.0% |
| HS 281410 - Ammonia: anhydrous | $1.1B | $348.0 | $748.4M | +54.3% | 1 | +0.0% |
| HS 292250 - Amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function | $1.1B | $44.1K | $699.0M | +37.2% | 1 | +0.0% |
| HS 284440 - Radioactive elements, isotopes, compounds, n.e.c. in heading no. 2844 alloys, dispersions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds: radioactive residues | $927.2M | $1.2K | $685.2M | +7.4% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $1.5B | $0.8 | $645.9M | -16.3% | 1 | +0.0% |
| HS 300213 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale | $961.6M | $1.6 | $643.7M | -66.9% | 1 | +0.0% |
| HS 340600 - Candles, tapers and the like | $1.0B | $386.0 | $640.9M | -3.1% | 1 | +0.0% |
| HS 300660 - Pharmaceutical goods: chemical contraceptive preparations based on hormones or spermicides | $1.2B | $38.5 | $604.6M | -9.2% | 1 | +0.0% |
| HS 360410 - Pyrotechnic products: fireworks | $518.2M | $74.8K | $603.8M | +13.0% | 1 | +0.0% |
| HS 293729 - Steroidal hormones, their derivatives and structural analogues: other than cortisone, hydrocortisone, prednisone (dehydrocortisone), prednisolone (dehydrohydrocortisone), halogenated derivatives of corticosteroidal hormones, oestrogen and progestogens | $320.8M | $9.3K | $584.1M | +78.9% | 1 | +0.3% |
| HS 330749 - Perfumes and deodorizors: perfuming or deodorizing preparations for rooms, (excluding those which operate by burning) | $676.1M | $130.0 | $579.1M | +3.4% | 1 | +0.0% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $733.2M | $450.6 | $547.9M | +44.7% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $154.9B calculated opportunity across 35 products.
- Switzerland, Liechtenstein (CHE): $27.7B calculated opportunity across 1 products.
- Germany (DEU): $16.8B calculated opportunity across 10 products.
- Canada (CAN): $6.3B calculated opportunity across 4 products.
- United Kingdom (GBR): $5.6B calculated opportunity across 3 products.
- Italy (ITA): $5.4B calculated opportunity across 2 products.
- Netherlands (NLD): $5.3B calculated opportunity across 1 products.
- France (FRA): $4.4B calculated opportunity across 3 products.
- Republic of Korea (KOR): $1.1B calculated opportunity across 1 products.
- Singapore (SGP): $1.1B calculated opportunity across 1 products.
- Australia (AUS): $751.8M calculated opportunity across 1 products.
- China (CHN): $750.5M calculated opportunity across 1 products.

## Growth stars

- HS 300390: +716.4% average CAGR, $2.2B calculated opportunity.
- HS 330290: +127.1% average CAGR, $803.3M calculated opportunity.
- HS 293719: +98.9% average CAGR, $29.5B calculated opportunity.
- HS 293729: +78.9% average CAGR, $584.1M calculated opportunity.
- HS 300212: +74.2% average CAGR, $4.3B calculated opportunity.
- HS 281410: +54.3% average CAGR, $748.4M calculated opportunity.
- HS 310530: +44.7% average CAGR, $547.9M calculated opportunity.
- HS 340220: +43.0% average CAGR, $1.2B calculated opportunity.
- HS 292250: +37.2% average CAGR, $699.0M calculated opportunity.
- HS 284190: +34.6% average CAGR, $1.7B calculated opportunity.

## Diversification opportunities

- HS 300490: 10 buyer markets, $70.5B calculated opportunity.
- HS 330300: 6 buyer markets, $6.1B calculated opportunity.
- HS 382200: 4 buyer markets, $5.2B calculated opportunity.
- HS 330499: 4 buyer markets, $4.6B calculated opportunity.
- HS 300215: 2 buyer markets, $30.7B calculated opportunity.
- HS 300214: 2 buyer markets, $25.9B calculated opportunity.
- HS 293359: 2 buyer markets, $11.7B calculated opportunity.
- HS 300390: 2 buyer markets, $2.2B calculated opportunity.
- HS 300290: 2 buyer markets, $1.7B calculated opportunity.
- HS 300432: 2 buyer markets, $1.3B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.